Figure 1From: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathwaysRepresentative immunostaining of osteosarcoma samples. Negative (-), positive (+) and strongly positive (++) samples for P-ERK1/2, MCL-1 and P-ERM expression.Back to article page
